AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Novo Nordisk Partners with Hims & Hers to Sell Wegovy, HIMS Stock Soars 28%
ByAinvest
Tuesday, Apr 29, 2025 10:32 am ET1min read
Hims & Hers will sell Novo Nordisk's weight loss drug Wegovy, starting at $599, through its telehealth platform. The deal aims to expand customer access as the FDA cracks down on compounded versions of the drug. Hims & Hers shares soared 28%, while Novo Nordisk stock rose 3%. The partnership is part of Novo Nordisk's efforts to increase access to branded Wegovy as compounding pharmacies are phased out.
Hims & Hers Health, Inc. (NYSE: HIMS) has announced a significant partnership with Novo Nordisk (NVO) to sell the weight loss drug Wegovy through its telehealth platform. The deal, which aims to expand customer access, comes as the FDA cracks down on compounded versions of the drug. Hims & Hers shares soared 28%, while Novo Nordisk stock rose 3% following the announcement.The partnership allows Hims & Hers to sell Wegovy at a discounted price of $599 per month, matching Novo Nordisk's pricing. This move is part of Novo Nordisk's broader strategy to increase access to branded Wegovy as compounding pharmacies are phased out [2].
The deal marks a significant turning point for Hims & Hers, which previously had to buy Wegovy from Novo Nordisk and resell it at inflated prices to maintain profitability. The new arrangement enables Hims & Hers to offer Wegovy at competitive prices, potentially expanding its customer base and driving revenue growth.
The partnership also signals a broader shift in the telehealth industry, as companies like Hims & Hers leverage their platforms to offer branded pharmaceuticals at affordable prices. This development is particularly notable in the context of the FDA's ongoing efforts to address the shortage of semaglutide injectable medicines, which include Wegovy and Ozempic.
Investors should closely monitor the performance of Hims & Hers shares, which have been volatile in recent months. The company's valuation metrics, such as forward EV-to-sales ratio and forward price to sales ratio, suggest that the stock may be undervalued relative to its peers [1].
References:
[1] https://seekingalpha.com/article/4779119-wegovy-today-ozempic-tomorrow-partnership-with-novo-is-hims-and-hers-comeback
[2] https://www.reuters.com/business/healthcare-pharmaceuticals/hims-hers-partners-with-novo-nordisk-sell-wegovy-its-platform-2025-04-29/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet